Fig. 1.

Tumor treatment effects of tumor-specific antigen and STING agonist co-administration in cisplatin-treated mouse model. C57BL/6 mice were subcutaneously injected with 2 × 10⁵ TC-1 cells/mouse on day 0. Mice were then treated intraperitoneally with 5 mg/kg cisplatin on days 15 and 18 and intratumorally with 20 µg/mouse E7 long peptide and 100 µg/mouse DMXAA on days 16 and 19. a Schedule flowchart. b Tumor mass was measured until the mice died or the tumor diameter was > 2 cm (n = 5). c Mouse survival was observed for 60 days (n = 5). d One week after the last vaccination, the tumor tissues and spleens of TC-1 tumor-bearing mice were harvested and re-stimulated with E7 short peptide and then analyzed for IFN-γ⁺ CD8⁺ T cells by flow cytometry (n = 5). IBM SPSS Statistics Base 22.0 was used for statistical analysis. *P < 0.05, **P < 0.01, ***P < 0.001